An exposure–safety analysis to support the dosage of the novel AKT inhibitor capivasertib
Cancer Chemotherapy and Pharmacology · 2025
DOI: 10.1007/s00280-025-04775-8 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Carlos Fernandez Teruel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Neoplasms, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Pyrimidines. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
This study aimed to evaluate capivasertib exposure–response relationships for clinical safety events to support dosage selection.
Methods
Data from 277 patients with solid tumors participating in three phase 1 studies were analyzed. Capivasertib 80–800 mg was administered as monotherapy orally twice daily (BID) on continuous or intermittent (4 days on, 3 days off [4/3] or 2 days on, 5 days off [2/5]) schedules. Relationships between exposure related metrics (dose, weekly dose, AUC, AUC PWD , C max , and C min ) and probability of safety endpoints (adverse event [AE] leading to dose discontinuation, AE leading to dose modification, serious AE [SAE], AE grade ≥ 3, AE grade ≥ 1, diarrhea AE grade ≥ 2, rash AE grade ≥ 2, hyperglycemia AE grade ≥ 3 and increased blood glucose > 13.9 mmol/L) were evaluated by logistic regression.
Results
Significant exposure–response relationships were identified for all safety endpoints evaluated, except for AE grade ≥ 1. The analysis suggested that most of the safety endpoints are driven by the total weekly exposure, whereas glucose elevations are driven by the exposure achieved within a dosing interval. The probability of experiencing an AE leading to dose discontinuation, AE leading to dose modification, SAE, AE grade ≥ 3, diarrhea or rash were lower with the 480 mg BID [4/3] schedule than with the 320 mg BID continuous schedule.
Conclusion
Significant exposure–response relationships were identified for safety endpoints when capivasertib was administered to patients with solid tumors suggesting that the intermittent [4/3] schedule is better tolerated than the continuous schedule due to lower total weekly exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Late Development Oncology, Oncology R&D, AstraZeneca, Cambridge, UK.
- Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA. diansong.zhou@astrazeneca.com.
Zitieren
APA
Teruel, C. F., Cullberg, M., González-García, I., Schiavon, G., & Zhou, D. (2025). An exposure–safety analysis to support the dosage of the novel AKT inhibitor capivasertib. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04775-8
Vancouver
Teruel CF, Cullberg M, González-García I, Schiavon G, Zhou D. An exposure–safety analysis to support the dosage of the novel AKT inhibitor capivasertib. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04775-8
BibTeX
@article{Teruel2025,
author = {Teruel, Carlos Fernandez and Cullberg, Marie and González-García, Ignacio and Schiavon, Gaia and Zhou, Diansong},
title = {An exposure–safety analysis to support the dosage of the novel AKT inhibitor capivasertib},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2025},
doi = {10.1007/s00280-025-04775-8}
}
EUVIMED